Expert Testimony at the Food and Drug Administration: Who Wants the Truth?

Narrative Inquiry in Bioethics 1 (2):78-82 (2011)
  Copy   BIBTEX

Abstract

This article has no associated abstract. (fix it)

Categories

Add categories

Keywords

Reprint years

DOI

10.1353/nib.2011.0046

Other Versions

No versions found

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 101,597

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

My notes

Similar books and articles

Narrative Symposium: Conflicting Interests in Medicine.Laura Jean Bierut, Sal Cruz-Flores, Laura E. Hodges, Anthony A. Mikulec, Govind K. Nagaldinne, Erine L. Bakanas, John F. Peppin, Joel S. Perlmutter, William H. Seitz, Edward Diao, Andre N. Sofair & David M. Zientek - 2011 - Narrative Inquiry in Bioethics 1 (2):67-90.
Recognizing and Managing Our Conflict of Interest.Laura Jean Bierut - 2011 - Narrative Inquiry in Bioethics 1 (2):67-68.
Should the Food and Drug Administration Limit Placebo-Controlled Trials?Max Goodman & Connor Pedersen - 2022 - Voices in Bioethics 8.
Limitations on the Capability of the FDA to Advise.Aaron S. Kesselheim & Leah Z. Rand - 2022 - American Journal of Bioethics 22 (10):15-17.
An Analysis of United States Food and Drug Administration Warning Letters Issued to Clinical Investigators from 1996 through 2011.Jessica A. Knowlton & Jim Y. Wan - 2011 - Journal of Clinical Research and Bioethics 2 (8).
Mifepristone Paternalism at the FDA.Jordan Paradise - 2023 - Journal of Law, Medicine and Ethics 51 (3):554-559.
Discourse, Dissonance, and Dualities: How Drug Shortages Are Understood and Communicated Among Health Care Professionals.A. Robert Samoilo & Irina Todorova - 2020 - Narrative Inquiry in Bioethics 10 (1):63-78.
Discourse, Dissonance, and Dualities: How Drug Shortages Are Understood and Communicated Among Health Care Professionals.A. Schleipman & Irina Todorova - forthcoming - Narrative Inquiry in Bioethics.
How confidential trial negotiations and agreements between the food and drug administration and sponsors marginalize local institutional review boards, and what to do about it.Howard Mann - 2006 - American Journal of Bioethics 6 (3):22 – 24.
A Defence of Pharmaceutical Paternalism.David Teira - 2020 - Journal of Applied Philosophy 37 (4):528-542.

Analytics

Added to PP
2014-02-02

Downloads
32 (#710,849)

6 months
11 (#356,365)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

No citations found.

Add more citations

References found in this work

No references found.

Add more references